A 2026 AB10015 post-hoc preprint reported 42.3% 5-year survival from amyotrophic lateral sclerosis symptom onset among patients originally assigned to masitinib 4.5 mg/kg/day with riluzole. The number is large for ALS, but the long-term comparison is historical and modeled rather than randomized placebo follow-up.1 Research Highlights 42.3% reached 5 years from onset: Ludolph et al. …
A 2026 medRxiv preprint found that a training-free speech biomarker tracked dysarthria severity across 890 speakers, 10 corpora, and 5 full-pipeline languages, with all 5 consonant d-prime features showing random-effects correlations with clinical severity (rho = −0.50 to −0.56; all p < 2e−4). Research Highlights Speech-severity signal was broad: Muller et al. evaluated 890 speakers …
A 2026 PRO-ACT analysis of amyotrophic lateral sclerosis (ALS) trial data found a signal that ordinary ALSFRS total-score slopes cannot even express: Shannon entropy trajectories diverged between pooled active and placebo arms, including a 5-month delay in peak Fine Motor distributional spread for active-arm patients.1 Research Highlights Entropy found an endpoint-level signal: Rodriguez analyzed 7,512 …
A 2026 Australian ecological model found that 20-year-lagged cumulative population blood-lead burden was nonlinearly tied to motor neuron disease mortality (lead spline p = 0.00024), while national insecticide use did not independently explain the curve after adjustment (p = 0.39).1 That is a real lead signal, but it is still population-level evidence, not proof that …